Insider Purchases: Inside the Buy

Tag: Biotech Investments

Digital illustration of a DNA strand fusing with glowing AI circuitry inside a futuristic lab, symbolizing Absci’s generative AI drug discovery technology.

Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!

AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.

Read entire article

Tags: Absci, ABSI, ABSI Stock, AI, AI in Biotech, AI Stocks, Almirall, AMD, Ark Invest, Biotech, Biotech Humor, Biotech Innovation, Biotech Investing, Biotech Investments, Biotech Partnerships, Biotech Stocks, Buy ABSI Stock, CFO Bought Shares, CFO Insider Buying, CFOBuyIn, Chief Innovation Officer Buying Shares, Director Insider Buying, drug discovery, FMR, Funanc1al, Funanc1al Edge, insider purchases, institutional ownership, investing humor, Oracle, Redmile Group, speculative stocks
A colorful digital illustration featuring Moderna's logo (MRNA) with a rising stock chart, symbolizing the biotech company's potential growth and innovation in gene-based therapies.

Moderna (MRNA): The Biotech Rollercoaster – Will This Gene Editor Reach the Top? 🎢💉

Moderna (MRNA) might be on the downhill since its peak in 2021, but its remarkable mRNA platform is fueling new therapeutic breakthroughs. With strong insider bets, a healthy pipeline, and institutional backing, Moderna could be an intriguing long-term play for investors. However, risks like intense competition and COVID sales deceleration remain. Should you bet on Moderna’s future or stay on the sidelines? Here’s what you need to know.

Read entire article

Tags: Biotech Investments, Biotech Stocks, Biotechnology, Biotechnology Innovation, COVID Vaccine, Gene Editing, healthcare stocks, Insider Purchases, Investment Insights, Moderna, Moderna CEO, mRNA, Paul Sagan, pharmaceutical stocks, Stephane Bancel